Showing 1 - 8 results of 8 for search 'Daniel B. Costa', query time: 0.03s
Refine Results
-
1
-
2
Uavnoma: A UAV-NOMA Network Model under Non-Ideal Conditions by Brena Lima, Nuno Fachada, Rui Dinis, Daniel B. Costa, Marko Beko
Published 2022-10-01
Article -
3
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active... by Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Daniel B. Costa
Published 2021-12-01
Article -
4
-
5
A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into... by Hollis Viray, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
Published 2024-03-01
Article -
6
CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. by Yi Cai, Ayako Hirata, Sohei Nakayama, Paul A VanderLaan, Elena Levantini, Mihoko Yamamoto, Hideyo Hirai, Kwok-Kin Wong, Daniel B Costa, Hideo Watanabe, Susumu S Kobayashi
Published 2015-01-01
Article -
7
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Published 2024-01-01
Article -
8
ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene by Zachary R. Schoepflin, MD, Emmeline Academia, PharmD, Soravis A. Osataphan, MD, Deepa Rangachari, MD, Sheida Sharifi, MD, PhD, Paul A. VanderLaan, MD, PhD, Daniel B. Costa, MD, PhD
Published 2023-04-01
Article